Coadministration of pexidartinib (a CYP3A4 inducer) with delicate CYP3A substrates may perhaps bring on critical therapeutic failures. If concomitant use is unavoidable, enhance the CYP3A substrate dosage in accordance with authorised products labeling.If coadministration of CYP3A4 inhibitors with fentanyl is critical, observe patients for respirat